1-tert-Butyl-1,2-dihydro-2-oxo-pyrimidin | 3739-89-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-tert-Butyl-1,2-dihydro-2-oxo-pyrimidin
• 英文别名: 1-tert-Butyl-2-oxo-1,2-dihydro-pyrimidin；1-tert-butyl-1H-pyrimidin-2-one；Pyrimidine, 1-t-butyl-1,2-dihydro-2-oxo-；1-tert-butylpyrimidin-2-one
• CAS: 3739-89-7
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: OPSLADCWNZWOGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• MGluR5 modulators V
  申请人：Wallberg Andreas

  公开号：US20070259860A1

  公开（公告）日：2007-11-08

  The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

  本发明涉及新化合物，以及用于它们制备的方法，它们在治疗中的应用以及包含这些新化合物的药物组合物。
• MGluR5 modulators I
  申请人：Wallberg Andreas

  公开号：US20070259862A1

  公开（公告）日：2007-11-08

  The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

  本发明涉及新化合物，以及用于它们的制备方法，它们在治疗中的应用以及包含这些新化合物的药物组合物。
• 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267668A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I). wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：X、R1、R2、R3和R4如规范中所定义。该发明还包括一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病是II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5
  申请人：GRANBERG Kenneth

  公开号：US20090111825A1

  公开（公告）日：2009-04-30

  The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

  本发明涉及新化合物，其制备方法，它们在治疗中的应用以及包含这些新化合物的药物组合物。
• Modified Nucleobases with Uniform H-Bonding Interactions, Homo- and Hetero-Basepair Bias, and Mismatch Discrimination
  申请人：Carnegie Mellon University

  公开号：US20210230680A1

  公开（公告）日：2021-07-29

  Described herein are divalent nucleobases that each binds two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone, such as in a γ-peptide nucleic acid (γPNA). Also provided are genetic recognition reagents comprising one or more of the divalent nucleobases and a nucleic acid or nucleic acid analog backbone, such as a γPNA backbone. Uses for the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.

  本文描述了二价核碱基，当它们被并入核酸或核酸类似物骨架（例如γ-肽核酸（γPNA））中时，每个核碱基可以结合两条核酸链，无论匹配或不匹配。此外，还提供了包含一个或多个二价核碱基和核酸或核酸类似物骨架（例如γPNA骨架）的基因识别试剂。还提供了包含二价核碱基的单体和基因识别试剂的用途。